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Abstract
Background: Access to medicines and the development of a strong national pharmaceutical industry are two
longstanding pillars of health policy in Brazil. This is reflected in a clear emphasis by Brazil’s Federal Government on
improving access to medicine in national health plans and industrial policies aimed at promoting domestic
pharmaceutical development. This research proposes that such policies may act as incentives for companies to
pursue a strategic Corporate Social Responsibility (CSR) agenda. CSR that supports Governmental priorities could
help companies to benefit significantly from the Governmental industrial policy. We sought to determine whether
CSR activities of Brazilian pharmaceutical firms are currently aligned with the Federal Government’s health
prioritization. To do so we examined key Brazilian health related policies since 2004, including the specific priorities
of Brazil’s 2012–2015 Health Plan, and compared these with CSR initiatives that are reported on the websites of
select pharmaceutical firms in Brazil.
Results: Brazil’s national health plans and industrial policies demonstrated that the Federal Government has
followed diverse approaches for improving access to medicines, including strengthening health care infrastructure,
increasing transparency, and supporting product development partnerships. Case studies of six pharmaceutical
firms, representing both public and private companies of varying size, support the perspective that CSR is a priority
for firms. However, while many programs target issues such as health infrastructure, health care training, and drug
donation, more programs focus on areas other than health and do not seem to be connected to Governmental
prioritization.
Conclusion: This research suggests that there are loose connections between Governmental priorities and
pharmaceutical firm CSR. However, there remains a significant opportunity for greater alignment, which could
improve access to medicines in the country and foster a stronger relationship between the Government and
industry.
Keywords: Access to Medicine, Brazil, Corporate Social Responsibility, Health policies, Industry-Government
alignment, Pharmaceutical industrialization, Universal health care system
Background
The Federal Government of Brazil has had a longstand-
ing and ambitious policy to increase access to medicine
for its population through pursuing the twin strategies
of establishing a universal health care system and by
promoting domestic pharmaceutical industrialization
[1–3]. This approach reflects how the Government aims
to improve access to medicines for its population and at
the same time promote economic development through
further industrialization. In the past decade, the Govern-
ment’s priorities in this area have shifted from a focus
on the local generic industry to promoting research and
development (R&D) capabilities in the private sector.
This further strengthens the ability of the domestic
pharmaceutical industry to improve the supply of
pharmaceutical products and support the Government’s
universal health care program. This shift and continued
support of the domestic industry has been accompanied
by efforts of the domestic industry to take a more active
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role in the country’s health sector through corporate so-
cial responsibility (CSR) policies.
The significant expertise and costs associated with
the development and testing of new drugs are such
that the process is typically only within the reach of
large private corporations. Even though universities,
and other public sector organizations, are heavily in-
volved in basic research in the pharmaceutical area,
the development of promising drug candidates is, in
most cases, licensed to private companies. To engage
in R&D in this sector requires a large amount of re-
sources, which in the case of Brazil are provided by
the Federal Government, largely through research
funding and by promoting public-private partnerships.
The Government has, for instance, invested in vaccine
research by state-owned laboratories such as Fiocruz
and the Butantan Institute and supports public-
private partnerships such as that between Fiocruz and
GlaxoSmithKline [1].
There can be various drivers for pharmaceutical com-
panies to take part in CSR [4]. Clearly, CSR helps pro-
mote a positive image of a company and is particularly
helpful if a company has had a sullied reputation in the
past. What is more, initiatives such as the Access to
Medicines Index (ATM), funded by the Gates Founda-
tion, is gaining notice given that it ranks how well select
companies are doing from a societal standpoint. The
ATM thus aims to put positive pressure on companies
to engage in activities that fit this agenda, as companies
are being compared against each other. Major inter-
national efforts to track and assess companies based on
CSR offer the potential for strong programming or lack
thereof to become associated with public approval. Ef-
forts by companies to improve their standing on mea-
sures such as the ATM shows that they strive to
improve their practices to reflect their commitment to
CSR and also that they understand that good CSR can
help improve their bottom line - more engaged em-
ployees and possibly shareholders that are more willing
to invest in a company that is perceived as doing good
works [4].
The Brazilian Federal Government has used two key
strategies in attempts to achieve its goals for the health
system: improving the governance of the health system
to be more responsive to citizen needs and supporting
domestic production and innovation of pharmaceuticals
to decrease dependency on foreign import [5]. As the
Government supports its domestic industry, there is an
incentive for companies to strengthen their own CSR
practices to reflect the Government’s two key strategies.
Such action would create a cooperative relationship be-
tween the Federal Government and the private sector, as
they support one another to attain the same public
health goals.
This paper examines the Brazilian Federal Govern-
ment’s strategies to improve access to medicine by ex-
ploring its key health related prioritizations. It also
examines the integration and alignment of the domestic
pharmaceutical industry with Government prioritization
through an analysis of CSR initiatives of Brazilian firms.
Specifically, this study analyzes the health policies of the
Workers Party Presidents, Luiz Inacio Lula da Silva
(2002–2010) and Dilma Rousseff (2011–2016), and how
their health policies promoted access to medicines and
innovation. We assess the key goals of the 2004–2007
National Health Plan, the 2006 Health Pact, the 2007
Mais Saúde Plan, the 2009 Brasil Maior Plan, and the
2012–2015 Health Plan. We further rely on information
on pharmaceutical companies’ CSR activities, provided
by them on their websites and in reports, to evaluate the
alignment of the Brazilian pharmaceutical industry with
the Federal Government’s areas of prioritization.
This research is highly relevant for various reasons, in-
cluding the growth of Brazil’s pharmaceutical market,
the importance Brazil’s Federal Government puts on
health and access to medicines, and the value that the
Government puts into fostering the domestic pharma-
ceutical industry. Some degree of reciprocity between
the Government and the domestic industry could yield
positive results for Brazilian citizens. Further, in light of
the corruption scandals that recently led to an impeach-
ment and suspension from the Brazilian Government of
President Dilma Rousseff, it seems likely that citizens
will be even more sensitized to the importance of the in-
vestment and operation policies and practices in the
country to ensure that they are geared towards the pub-
lic good.
The paper is organized as follows. First, the literature
review will be presented on the concepts of CSR,
followed by a review of literature on access to medicine
and CSR in Brazil. We will then address the key research
questions of this paper and analyze Brazil’s health related
policies as well as the CSR areas focused on by Brazilian
pharmaceutical firms, and examine their alignments.
Lastly, we will present the main messages drawn from
this research.
CSR and the private sector
The global pharmaceutical market is enormously lucra-
tive. Annual global pharmaceutical spending is fore-
casted to reach US$1.2 trillion by 2016 and annual
spending growth will increase from US$30 billion in
2012 to US$70 billion in 2016 [6]. Pharmaceutical ex-
penditures are typically one of the top healthcare expen-
ditures for governments globally and can reach as high
as 50% of the total health spending in some developing
countries [7]. Brazil is no exception, as its pharmaceut-
ical market is the second largest in the emerging world,
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with the value of the prescription drugs sold to Brazil’s
middle class in 2010 valuing at $8 billion dollars [8].
Such high levels of profitability have been increasingly
exposed to new standards and regulatory frameworks, as
a result of increased pressure from employees, commu-
nity groups, non-governmental organization (NGOs)
and governments to engage in activities that are morally
and ethically sensitive [9]. This phenomenon, called
CSR, is defined as when companies actively do “good”
outside of the scope of their business, often with a com-
plementary strategic goal of securing the loyalty of cus-
tomers [4]. While the reason behind the emergence of
CSR is based on ‘doing the right thing’ without taking
into consideration the financial implications of such be-
haviour, companies are also aware that CRS has a stra-
tegic component, as it allows for companies to add value
to their products by appearing socially responsible to the
consumer [9]. Even when their actions are not directly
tied to a particular product, CSR allows them to gain or
maintain a positive reputation among consumers.
CSR reflects the importance of outside stakeholders,
as external pressures from NGOs and the public have
had a clear influence on business actions. Some authors
have also emphasized the vital role of internal stake-
holders, particularly employees, in driving company ac-
tions [4], as they are in charge of creating and
implementing corporate policies. Smith notes that there
is an increased pressure for companies to have CSR pol-
icies [10]. Using the example of access to medicines in
the pharmaceutical industry, he finds that although the
motivations to engage in CSR may be normative, there is
also a strategic business incentive driven by increased
public pressure. He suggests that while company actions
may be in the interest of public health they also “reduce
the risk of eroding shareholder value” [10].
Porter and Kramer call CSR an “inescapable priority”
for businesses [11]. The authors argue that CSR should
not be viewed as a separate entity, which competes with
the prime interests of a business (profit through its given
product) but can rather be an integral component of its
strategy. CSR is then viewed not as a push-back against
society or a giving-in to societal interests but rather as a
way to engage with society to attain the greatest benefits.
CSR activities can then fall into generic activities that
target areas affected by the company’s value chain or
areas that are harmed as a result of the company’s activ-
ities. Furthermore, to be effective, CSR should be coordi-
nated, measurable, and have targets just as any other
business strategy.
The ATM has been evaluating select multinational
pharmaceutical companies on the above criteria for the
past 10 years [12]. It measures activities that would fall
under the categories of value chain and mitigating harm
in Porter and Kramer’s approach. Importantly, today
CSR is a greater part of boardroom discussion rather
than it being an isolated department of the company.
The results of the ATM demonstrate that companies
have begun to recognize the importance of CSR for its
companies “brand” and are likely to approach it as a
strategic endeavour.
Access to medicines and CSR in Brazil
Brazil is the largest country in Latin America, with a
population of around 208 million people dispersed
across five regions (North, Northeast, Central-West,
Southeast, South) [13]. These macro-regions are further
divided into 27 states and 5,564 municipalities. In 2012,
its pharmaceutical market reached almost US$26 billion
after several years of double-digit growth (about 3% of
the global market) [14].
The universal health care system in Brazil, Sistema
Único de Saúde (SUS), was established pursuant to the
1988 Constitution which guaranteed universality, equity,
and a decentralized health system [5, 15]. Throughout
the 1990s, the details of decentralization were decided
upon and outlined across three pieces of legislation, the
Basic Operational Norms of 1991, 1993, and 1996 [16].
The responsibilities for the health system are distributed
among the federal, municipal, and state governments.
The Federal Government is responsible for health sur-
veillance, management of drug registration and quality,
evaluation of the health system, and management of spe-
cific health areas such as indigenous health. Municipal
governments implement health actions for their citizens
with funding drawn from all levels of government. In
turn, the state level provides technical support and fund-
ing for municipal governments [17]. With a highly
decentralized health system that includes municipalities,
states, and the Federal Government, health policy-
making in Brazil is a complex enterprise.
The commitment to universal access to health care is
widely recognized as a defining feature of Brazil’s 1988
Constitution [5]. However, the promise of access to
medicines came in the early 1990s as a result of activism
for the HIV/AIDS epidemic [18]. There have been ex-
tensive governance challenges for putting the access to
medicines commitment into practice. Effectiveness, effi-
ciency, equity, and inclusiveness are all key principles,
which define good governance. Extensive research on
the status of access to medicines in Brazil has shown
that all of these principles have been challenging to
achieve. Entrenched inequalities within and between
states have affected health care utilization [19] and have
resulted in very different procurement prices, particu-
larly affecting the purchasing capacity of smaller states
[20]. Vieira and Zucchi found that municipalities with
under 10,000 residents on average paid more per capita
on medicines than larger states, with significant
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differences between regions as well [20]. After conclud-
ing that these differences could not be attributed to vari-
ations in health-seeking behaviours, the authors
suggested that unequal negotiating power between states
is likely responsible. There is also the impact of a parallel
private system, which affects access to medicines by in-
creasing out-of-pocket (OOP) costs. Although OOP pay-
ments are progressive, with the rich paying more than
the poor, estimates by the WHO show that they still ac-
count for 47.2% of private spending, which is about 54%
of total expenditure on health [21].
Availability is also a consistent challenge for the gov-
ernment in ensuring access. Providing medicines is a
massive undertaking for a government, requiring not
only sufficient funds to purchase the necessary medi-
cines, but a pharmaceutical supply chain equipped to
maintain sufficient stock in all pharmacies. Access and
affordability studies by Bertoldi et al. have found weak-
nesses in both of these areas [22]. When public sector
facilities were examined, availability of the lowest-priced
generics ranged from 8.9 to 23.3% across six cities. This
number improved when looking at branded generics
(called “similares” in Brazil) (55.8 to 70.2%). There is
thus a very clear need to identify ways to improve access
to medicine in the country, involving both the public
and the private sectors.
Methods
To understand better how well aligned the pharmaceut-
ical sector in Brazil is with the Governmental health pri-
orities, we conducted a study that addressed the
following questions:
1) What are the main focal areas that Brazil’s Federal
Government is promoting to enhance access to
medicine in the country? and,
2) How well are the CSR strategies of the Brazilian
pharmaceutical industry aligned with the
Government’s focal areas for access to medicine?
We conducted a literature review covering the years
from Luiz Inacio Lula da Silva’s presidency in 2002 to
2016, by searching a number of databases, including
SciElo, Scopus, Google Scholar, Factiva, Pubmed as
well as government websites and press releases. Initial
key terms used in the searches for academic papers
were: Brazil, Health Policy, Health System, Innovation,
Governance, Pharmaceutical Policy, Domestic, and In-
dustry. Boolean operators and wild card functions
were used to broaden the searches. The terms Medi-
cine and Access were used in combination with the
main terms but were too broad when used independ-
ently. The terms used were free-text and searches
were of all-text and keywords. Focused searches for
the following specific programs were expanded as they
were identified: Product Development Partnerships,
Health Industrial Complex, National Health Plans.
The academic literature was used to identify the key
health related policies during the time frame we fo-
cused on and guide searches for policies and laws
established by the Federal Government, which were
then retrieved from the Government records [23].
To identify the health priorities of the Federal Govern-
ment in Brazil we reviewed the health policy literature
both through a study of international peer-reviewed arti-
cles and original policy documents obtained from Gov-
ernment websites. Inclusion criteria covered two areas,
the development of health policy in Brazil and the
growth of the domestic pharmaceutical industry. Articles
were included if they provided background and analysis
on either or both of these topics. Specific searches on
each of the health plans were conducted on government
law databases. Five-year national health policies were ex-
amined to identify the Federal Government’s main
health priorities, which clearly state what health prior-
ities the Government wants to focus on in the specific
time period.
In this research we did not want to define what consti-
tutes CSR by Brazilian pharmaceutical firms but rather rely
on how firms define their CSR activities. The selection of
case study companies was done based on a consultation
with all researchers. We used purposeful sampling of the
firms, where we tried to maximize the variance between
the firms chosen. Factors taken into consideration were:
company size in terms of employee numbers and market
impact, whether the firm was private or public, and other
ownership arrangements. We decided to choose some of
the largest Brazilian pharmaceutical companies (Ache
Farmaceutica, EMS and Eurofarma) and used IMS Health
Data on market share to identify those firms [24]. We in-
cluded also companies that have more modest market
share (Apsen Farmaceutica and Biolab Sanus Farmaceu-
tica). We decided to include Fiocruz, a public organization,
given its unique status as a government owned institution
conducting research and manufacturing of health products.
We therefore included in our study an examination of the
CSR activities of the two production-oriented units of Fio-
crus, Biomanguinhos and Farmanguinhos. The broad activ-
ities of the main Fiocruz organization were not included as
its main role is research as a public health institution. We
included both a publicly traded firm (Ache Farmaceutica)
and privately owned ones, including a private family owned
firm (EMS). As we wanted to focus on domestic pharma-
ceutical firms we excluded all subsidiaries of multinational
firms in Brazil. We retrieved information on the sizes, own-
ership arrangements and focal products from the compan-
ies’ websites. In Table 1 we list the selected companies that
we focused on in this study.
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Case studies were carried out through a comprehensive
review of every company website, including annual reports.
We collected information on company origins, company
size, therapeutic categories, innovation strategy, and CSR
activities and policies. We compared English and Portu-
guese language sites as often the English language sites con-
tained less information. Translation was completed when
this was the case. Typically information on the CSR activ-
ities was under special headings such as ‘Social Responsibil-
ities’ or ‘Community Sustainability’. In some cases we
gleaned information on CSR activities from the companies’
annual reports.
All CSR projects listed on company sites were extracted
to a separate document, with links to the original source.
These were coded and categorized by one author (NO),
and then reviewed and revised by a second author (HT).
Analysis of the companies included comparison of the cat-
egories of the CSR activities with national health policies to
assess whether there was alignment with the Federal
Government.
Results
Focal areas to enhance access to medicine in Brazil
To address our first research question: What are the
main focal areas that Brazil’s Federal Government is
promoting to enhance access to medicine in the coun-
try?, we examined the health policies of the Workers
Party Presidents Luiz Inacio Lula da Silva (2002–2010)
and Dilma Rousseff (2011–2016) and assessed their
focus on access to medicines and innovation. Managing
and improving health has been a governmental priority
since the passing of Brazil’s constitution in 1988. Direct
health policy is one way in which change can be made.
However, strengthening the infrastructure and industry
contributing to health can be equally important. For
Brazil, this has meant focusing on two areas: the gov-
ernance of the public health system and the strengthen-
ing of the domestic pharmaceutical industry.
An overview of health related prioritization
Critical changes affecting the governance of the public
health system were made in 1998. The National Drug
Policy was passed which included: reforms of the essen-
tial medicines list (RENAME) (requiring an essential
medicine list (EML) guidelines for rational use of medi-
cines), pharmaceutical surveillance (infrastructure, ge-
nerics policies, drug registration), and pharmaceutical
services (financing, decentralization of essential medi-
cines and medicines availability) [25]. This policy
focused on innovation and equity, transparency, ac-
countability, and inclusiveness. Through this policy, the
Federal Government pledged to provide free access to all
medicines on RENAME for citizens using the SUS, al-
though the government has yet to meet this goal [22].
The Generic Drugs Law was established in 1999 and
provided a further opportunity to manage costs and im-
prove access to medicines. This law established regula-
tions defining the parameters of what constitutes a
generic drug and therefore creating an opportunity for
the domestic production of these products [26].
In addition to the National Drug Policy, there have
been health plans outlining targets for the country every
3 years [27–29]. These plans have recognized the limita-
tions of the health system and have sought to overcome
them. Supplementing the health plans there has been
the Health Pact focusing on the coordination and rela-
tions between the three levels of government (federal,
state, and municipal) [30]. Another relevant plan, Brasil
Maior, has targeted industrial policy with a component
on strengthening the healthcare industry [31]. Table 2
lists some key recent Governmental policies that have
been relevant to the health sector in the country and it
includes both health and industrial policies.
The Brazilian Federal Government consistently treats
access to medicines as an important goal for the health
system. In the 2004–2007 National Health Plan, the sec-
ond goal specifically highlighted access to pharmaceut-
ical services [27]. It established the Farmacia Popular
Table 1 Case Study Companies
Company Ownership status Founded Size (employees) Products
1. Ache Farmaceutica [39] Publicly-traded 1961 >2000 Generics, branded generics,
and innovative
2. Apsen Farmaceutica [40] Private 1969 ~700 Generics, branded generics,
and early stage innovative
3. Biolab Sanus Farmaceutica [41] Private 1997 2000 Branded generics, innovative
4. EMS [42] Private, family-owned 1964 >4500 Generics, branded generics,
innovative
5. Fiocruz; Biomanguinhos
and Farmanguinhos [43, 44]
Public (government) 1900 as public health
agency, pharmaceutical
divisions founded in 1976
Generics for government
purchase only
6. Eurofarma [45] Private 1972 >6000 Generics, branded generics,
innovative
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program. This program established public pharmacies
and partnered with private pharmacies to increase access
to commonly prescribed medications. Medications are
either free in public facilities, have an administrative co-
payment in facilities under the control of Fiocruz, or
have a 90% subsidy of the reference price in private facil-
ities [32, 33]. In 2011 the program was expanded to have
a component providing free medications for diabetes
and hypertension. Some research has shown the free
medication having substantially reduced the expendi-
tures on medicines paid by poor people in Brazil and the
poorest quintile of the population studied relied on free
medicines for 80% of their needs [34].
The 2006 Health Pact included requirements for en-
suring access to medicines in several specific areas of
care, including health of the elderly and maternal mor-
tality [30]. In the 2008–2011 Plan, access to medicines
highlighted goals for ensuring quality and increasing the
supply of medicines [28]. Finally, in the 2012–2015 Plan,
one of the goals was to ensure access to medicines by
improving care at both primary and specialized facilities,
with another focused on strengthening the pharmaceut-
ical assistance program which guarantees free provision
of medicines on the RENAME list [29].
One approach the Federal Government has pursued to
improve access to medicine is to strengthen the govern-
ance of the health care system to encourage more know-
ledge flow between the different components of the
system. The primary focus has been on citizen participa-
tion, engaging the public in the improving the health
care system [5]. There are also planned interventions
that target improvements in management of specific
programs as well as increasing transparency. In the
2004–2007 Health Plan, goals included provisions for
improving coordination in primary care, ensuring that
the system is being responsive to actual health needs, in-
creasing participation in the management of the SUS for
citizens and health workers, and increasing transparency
and availability of health information [27]. In the Health
Pact of 2006, the emphasis continued to be on citizen
empowerment and increasing participation as well as
improving accountability and management in the SUS
[30]. In contrast, the 2008–2011 Health Plan emphasizes
improving management of the SUS and ensuring that
good quality medicines are being provided [28]. The
2012–2015 Health Plan, discussed further below, targets
more specific areas of the health sector [29]. Here, tar-
gets include improving coordination of services for men-
tal health and indigenous health, regulating the private
health sector, strengthening labour and citizen relations
and improving enforcement measures to increase effi-
ciency in the SUS.
Industrial policy for access to medicines
Some industrial policies from the past decade demon-
strate how the Brazilian Federal Government has sup-
ported the domestic pharmaceutical industry as a part
of improving access to medicine in the country. Ref-
erences to industrial policy fostering better health can
be found in both the health plans listed above as well
as in in the Brasil Maior plan [31]. Where innovation
is included in the health plans, the emphasis is on
fostering the growth of domestic businesses and in-
creasing the development and availability of new
medicines and technologies. In 2003, the Government
also established a Secretariat of Science, Technology
and Strategic Inputs to promote innovation in the
health sector which it further relied on in promoting
industrialization of the domestic pharmaceutical sec-
tor [35, 36].
In the 2004–2007 Health Plan, there is a target for
developing a national policy in science, technology and
health, with a specific reference to supporting domestic
technology [27]. Another point further describes the
need to invest in health through industrial and technol-
ogy policy with the aim of national autonomy in produ-
cing key materials. The 2008–2011 Health Plan
continues with this standard, aiming to increase domes-
tic production of pharmaceuticals and medical supplies
[28]. Health-focused goals of the Brasil Maior plan en-
courage the expansion of new businesses, strengthening
and diversifying exports, and expanding funding for
product development [31]. The 2012–2015 Health Plan
further includes points on domestic research and
Table 2 Key Health Related Policies in Brazil
Plan Sector Type President
National Health Plan
2004–2007 [27].
Health Three-year plan Lula da Silva
Health Pact 2006 [30]. Health Coordination across federal,
state and municipal governments
Lula da Silva
Mais Saúde 2008–2011 [28]. Health Three-year Plan Lula da Silva





Health Three-year plan Dilma Rousseff
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production of pharmaceuticals and also prioritizes
Brazil’s pharmaceutical industry interests on an inter-
national scale [29].
In 2008, Decree 12 established the so-called Health
Industrial Complex (HIC), a system incorporating the
major actors and their alignments, which reflects the
connections between healthcare and economic develop-
ment [37]. The HIC has also been incorporated as a pil-
lar of the 2008–2011 Plan and Brasil Maior [38]. This is
one of the clearest manifestations of the Government’s
focus on strengthening domestic productive capacity.
The HIC is a collaborative effort between the Ministry
of Health, Ministry of Development, Industry and
Foreign Trade and the Ministry of Science and Technol-
ogy. Additional important participants are the Brazilian
Development Bank and the Brazilian Innovation Agency,
two of the main funding bodies. The law sets up working
groups, committees, and other organizing bodies with
the mandate to increase domestic innovation and foreign
competitiveness. It further provides financial incentives
for strategic areas, by using health system purchasing
power, developing networks to support good quality and
competitiveness in domestic products, and streamlining
administrative/regulatory processes.
The discussion above therefore demonstrates the ex-
pectations the Federal Government in Brazil places on
the domestic pharmaceutical industry to enhance access
to medicine in the country and the different initiatives
to ensure alignments within the pharmaceutical sector.
Priorities in the national health plan 2012–2015
Apart from emphasizing access to medicine and integra-
tion of health and industrial policies, the newest health
plan lists further key areas for promoting health in the
country [29]. In Table 3, the main priorities in the 2012–
2015 Health Plan, as outlined in the document are listed.
From Table 3, one can see that the priorities listed in
the health plan focus on diverse areas. Many of them
focus on health care in general or health care of specific
populations such as maternal and child health, indigen-
ous health and mental health. There are also health pro-
motion and health education priorities. Further, some
priorities are more policy oriented, health management
or health diplomacy focused. The areas that the Brazilian
Federal Government is pursuing do cover a wide
spectrum. Brazilian pharmaceutical firms have, therefore,
a wide range of possibilities in aligning their CSR activ-
ities with priorities of the Brazilian Government.
This section has demonstrated that the Brazilian Gov-
ernment has a broad focus on improving health of its
population. Access to medicines is consistently on the
Brazilian Government’s agenda and it is integrated into
the health sector goals for the country as well as indus-
trial policies of the country. The following section will
Table 3 Priorities in Brazil’s 2012–2015 Health Plan
Areas
1 Guarantee equitable and timely
access to good quality medicines,
through improvements of primary
and specialized care
Health care, general
2 Improvement of emergency care
services
Health care, general
3 Increase focus on maternal and child
health through the Stork Program,
emphasizing vulnerable regions
Maternal and child health;
Vulnerable regions
4 Strengthen mental health networks,
focusing on addictions to cocaine
and other drugs
Mental health and addiction
5 Guarantee attention to health of the
elderly and those with chronic
conditions through strengthening of




6 Implement a sub-system in health-
care focused on indigenous health in
compliance with health practices and
traditional medicines, maintaining re-




7 Use health promotion and




8 Guarantee pharmaceutical assistance
through SUS
Health access, general
9 Improve regulation of the
supplementary health system,
articulating the public/private
relationship and ensuring more
rational and good quality care
Regulation, general
10 Strengthening science, technology
and innovation around the national
agenda for economic, social and
sustainable development with the
aim of reducing vulnerabilities in
access to health
Health policy, general
11 Contributing to appropriate training,
allocation, qualification, valuing(?)
and the democratization of work
relations for SUS employees
Health education, general




management and a focus on results,




13 Qualification for direct enforcement
instruments, generating gains in
productivity and efficiency in the SUS
Health management
14 Promotion of Brazilian interests
internationally in the field of health,
sharing experiences of SUS with
other countries in accordance with
the Brazilian Foreign Policy
Health diplomacy
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examine the key CSR areas of Brazil’s pharmaceutical
sector and the sector’s alignment with Federal Govern-
ment’s health prioritization in the country.
CSR policies’ alignment with governmental prioritization
To answer our second question: How well are the CSR
strategies of the Brazilian pharmaceutical industry
aligned with the Government’s focal areas for access to
medicine? we examined CSR activities of six Brazilian
pharmaceutical firms. As described above we looked at
the websites of the firms and annual reports when avail-
able to examine to what extent they describe their en-
gagement in CSR initiatives and the types of activities
listed. Table 4 presents classification of the areas that
Brazilian pharmaceutical firms list as their CSR
activities.
Table 4 shows that the firms have a number of pro-
grams aimed at fulfilling their CSR. Many of these are
supporting health related activities. The programs sup-
porting health care, health care infrastructure, health
care training and seniors, all have a definite emphasis on
improving access to medicine and medical services in
the country. The programs do therefore align with Gov-
ernmental prioritization on improving health care in
Brazil and to the priority to guarantee equitable and
timely access to good quality medicine. Senior’s health is
also targeted by one company. It is also noteworthy how
many programs focus on environmental issues, such as
waste management programs, which reflect an emphasis
on promoting sustainable development. Still the connec-
tion to specific Governmental prioritization is tenuous.
There is, for instance, a good alignment with child
health emphasized by the Brazilian Government but lack
of focus on maternal health, mental health or indigenous
health, which are all governmental priorities. A large
proportion of the CSR activities are not directly health-
related but rather focused on areas such as training in
general, the arts or sports. These tend to be traditional
areas supported by any industrial firms to demonstrate
their good citizen role, rather than attempts to reinforce
governmental health policies. In general, the case study
analysis suggests that pharmaceutical firms are promot-
ing their good citizen role to enhance general goodwill
in their CSR programmes rather than reinforcing Gov-
ernmental strategies to promote access to medicine and
health services in specific areas.
Discussion
The Brazilian Federal Government has set up clear
health priorities that can serve as a direction for the
pharmaceutical firms’ CSR activities. There has been
consistent emphasis on areas such as primary health
care, senior health and maternal and child health. Our
research, however, identifies only loose connections be-
tween the companies’ CSR activities with the Federal
Government’s health priorities as many of the firms’ pro-
grams are in areas other than health. Furthermore, pro-
grams that do emphasize health for the most part do not
seem to select their area of focus based on governmental
prioritizations. There seems to be clear interest from the
firms examined in these case studies to develop robust
CSR programming, with the potential to increase the
focus on health. This motivation and the current lack of
alignment therefore represent a lost opportunity to
strengthen the HIC complex and make it more
coherent.
We found in our investigation that Brazilian pharma-
ceutical companies can target their CSR programs to-
wards the same areas as the Federal Government and
thereby ideally strengthen the HIC complex and access
to medicine in the country. Globally, multinational
pharmaceutical companies have recognized the import-
ance of access to medicines and CSR. Brazilian compan-
ies could do the same on a national scale. The Brazilian
companies receive significant benefits from the Federal
Government as it seeks to improve access via industrial
Table 4 CSR Initiatives of Select Brazilian Firms
Area of programs Number of
programs
Firms active
Health carea 7 Apsen, Biolab, Eurofarma,
Fiocruz




4 Apsen, EMS, Fiocruz
Health care training 6 Apsen, Eurofarma, Fiocruz
Donation or discount
of medicines
4 Ache, Eurofarma, Fiocruz
Senior support 2 EMS
Training (not health
care related)








8 Ache, Eurofarma, Fiocruz
Social issues 10 Ache, Eurofarma, EMS, Fiocruz
Research 2 Apsen, Biolab
Child care support 4 Ache, EMS, Eurofarma, Fiocruz
Arts and culture 8 Apsen, Biolab, EMS, Fiocruz
Sport 2 Apsen, Fiocruz
Otherc 10 Ache, Eurofarma, Fiocruz
aExamples include: Complementary dental care, support for cancer care and
hearing and respiratory conservation programs
bExamples include: information on safe medication use for patients, lectures
on health issues, such as on sexual health and pregnancy as well as on
health policy
cIncludes employee recognitions, visits to firms, housing support, support to
deaf employees, meditation room, etc.
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policy. Should companies increase their focus on align-
ing CSR with national health goals, they could be in a
more competitive position to receive further benefits
from the Government’s continued industrial policies.
Such reciprocity would demonstrate buy-in towards ac-
cess to medicines and the impact of opening
governance.
There are, however, a number of limitations to this re-
search. Unfortunately information is lacking on the exact
funding of the CSR programs of the firms. This, there-
fore, diminishes the potential of comparing the CSR em-
phasis of the firms as some may have few programs that
are well funded whereas other firms may have many
small programs. The value of the comparisons above is
therefore limited to identification of the themes of the
CSR programming. Further, this paper only looks at the
CSR activities of the Brazilian pharmaceutical firms ra-
ther than their core activities. It is possible that there are
better alignments between their core activities and gov-
ernmental prioritization. By looking at the alignment
through the CSR lens, it appears, however, that the activ-
ities in general lack focus and present a lost opportunity
to reinforce governmental prioritisation on access to
medicine. There is, thus, scope to do further research to
get a fuller picture of the relationship between CSR ac-
tivities of Brazilian pharmaceutical firms and the Federal
Government’s health priorities.
Conclusion
Our research article examines if and how the Federal
Government of Brazil’s policy to increase access to medi-
cine, by establishing a universal health care system and
by promoting domestic pharmaceutical industrialization,
may have created incentives for pharmaceutical compan-
ies to pursue a strategic CSR agenda that is in line with
the Government’s objectives. We sought to determine
whether such strategic approaches are currently in place
by comparing Brazil’s health and industrial policies with
the CSR programs of major pharmaceutical firm based
in Brazil. As Brazil is undergoing significant political and
economic upheavals, there is an opportunity now to ob-
serve the Brazilian pharmaceutical industry as it pursues
expansion into innovative work at the same time as the
Government seeks to ensure the sustainability of its
health goals.
Brazil’s national health plans and industrial policies
demonstrated that the Federal Government has followed
a number of strategies for improving access to medi-
cines, including strengthening health care infrastructure,
developing subsidy programs, increasing transparency,
and supporting product development partnerships. Case
studies of six pharmaceutical firms were presented,
representing both public and private companies of vary-
ing size. These suggest there are some connections
between Governmental priorities and pharmaceutical
firm CSR, though it is not clear that these were stra-
tegically established. There remains a significant oppor-
tunity for greater alignment, which could improve access
to medicines in the country and foster a stronger rela-
tionship between the Government and industry. It re-
mains to be seen whether Brazilian pharmaceutical
companies will deepen their CSR policies to better re-
flect the goals of Government. This paper suggests that
if they were to do so, there would be significant benefits
for the Brazilian population.
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